<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="208">
  <stage>Registered</stage>
  <submitdate>10/12/1999</submitdate>
  <approvaldate>10/12/1999</approvaldate>
  <nctid>NCT00004042</nctid>
  <trial_identification>
    <studytitle>Monoclonal Antibody F19 in Treating Patients With Advanced or Metastatic Cancer</studytitle>
    <scientifictitle>A Phase I Dose-Escalation Study of BIBH-1 in Patients With Advanced or Metastatic Fibroblast Activation Protein-Positive Cancer</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>MSKCC-98068</secondaryid>
    <secondaryid>BOEH-1152.1</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Colorectal Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Bowel - Back passage (rectum) or large bowel (colon)</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Other interventions - monoclonal antibody F19
Treatment: other - iodine I 131 monoclonal antibody F19

Other interventions: monoclonal antibody F19


Treatment: other: iodine I 131 monoclonal antibody F19


</interventions>
    <comparator />
    <control />
    <interventioncode>Other interventions interventions</interventioncode>
    <interventioncode>Treatment: other</interventioncode>
  </interventions>
  <outcomes />
  <eligibility>
    <inclusivecriteria>DISEASE CHARACTERISTICS: Histologically confirmed unresectable, advanced and/or metastatic
        disease: Colorectal cancer Measurable or evaluable disease Epidemiologically proven
        fibroblast activation protein positive Failed or refused conventional treatment, and
        unlikely to derive significant benefit from conventional treatments No active CNS
        metastases No new or progressive lesions on CT scan, more than 3 months since treatment
        (i.e., surgery or radiotherapy) for brain metastases, and/or not receiving mitomycin
        Hormone receptor status: Not specified

        PATIENT CHARACTERISTICS: Age: 18 and over Menopausal status: Not specified Performance
        status: Karnofsky 70-100% Life expectancy: At least 4 months Hematopoietic: Absolute
        granulocyte count at least 1,500/mm3 Platelet count at least 100,000/mm3 Hepatic: ALT/AST
        no greater than 3 times upper limit of normal Bilirubin less than 2 mg/dL Renal: Creatinine
        no greater than 2.0 mg/dL Other: Not pregnant or nursing Fertile patients must use
        effective contraception No other serious illness No active infections requiring antibiotics
        No bleeding disorders No other diseases that may potentially interfere with obtaining
        accurate study results

        PRIOR CONCURRENT THERAPY: Biologic therapy: At least 4 weeks since prior immunotherapy No
        prior murine, chimeric or humanized antibody and/or antibody fragment Chemotherapy: See
        Disease Characteristics At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas
        and mitomycin) Endocrine therapy: No concurrent systemic corticosteroids (except for acute
        management of allergic-type events) No concurrent immunosuppressive agents Radiotherapy:
        See Disease Characteristics Surgery: See Disease Characteristics Recovered from surgery
        Other: At least 4 weeks since other prior investigational agents</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria />
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/11/1998</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>24</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2009</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
    <hospital>Ludwig Institute for Cancer Research-Sydney Branch - Sydney</hospital>
    <postcode>2006 - Sydney</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Memorial Sloan Kettering Cancer Center</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>National Cancer Institute (NCI)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver
      tumor-killing substances to them without harming normal cells.

      PURPOSE: Phase I trial to study the effectiveness of monoclonal antibody F19 in treating
      patients who have advanced or metastatic cancer.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00004042</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sydney Welt, MD</name>
      <address>Memorial Sloan Kettering Cancer Center</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>